Europe Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II), By Indication (Oncology, Diabetes), By Study Design, By Service Type, By Sponsor, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Europe Clinical Trials Market Growth & Trends
The Europe clinical trials market size is expected treach USD 32.43 billion by 2030, according ta new report by Grand View Research, Inc. The market is expected texpand at a CAGR of 6.86% from 2025 t2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed tthe market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely tpromote the growth of the market.
The demand for personalized medicines has significantly improved in the region owing tsignificant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is tcollaborate research and health policy taccelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely tpromote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.
For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely tincrease the demand for researchers tdevelop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely tpromote market growth.
Europe was one the worst affected region by the COVID-19 pandemic, owing twhich public organizations in the region made significant funding in research tboost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged tinvest USD 679 million tsupport the development of COVID-19 vaccines. Owing tthe pandemic several research centers were shut down due tthe national lockdown implemented by the government authorities, owing twhich several clinical trial organizations opted for in silictrials and virtual clinical trials tspeed up the research process. Such actions had profited the growth of the market.
Europe Clinical Trials Market Report Highlights
Europe Clinical Trials Market Growth & Trends
The Europe clinical trials market size is expected treach USD 32.43 billion by 2030, according ta new report by Grand View Research, Inc. The market is expected texpand at a CAGR of 6.86% from 2025 t2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed tthe market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely tpromote the growth of the market.
The demand for personalized medicines has significantly improved in the region owing tsignificant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is tcollaborate research and health policy taccelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely tpromote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.
For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely tincrease the demand for researchers tdevelop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely tpromote market growth.
Europe was one the worst affected region by the COVID-19 pandemic, owing twhich public organizations in the region made significant funding in research tboost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged tinvest USD 679 million tsupport the development of COVID-19 vaccines. Owing tthe pandemic several research centers were shut down due tthe national lockdown implemented by the government authorities, owing twhich several clinical trial organizations opted for in silictrials and virtual clinical trials tspeed up the research process. Such actions had profited the growth of the market.
Europe Clinical Trials Market Report Highlights
- The phase I trial segment is projected twitness a remarkable growth rate of 7.49% over the forecast period. This can be attributed tthe significant R&D spending by public and private organizations tsupport new researches
- The interventional study design segment held the largest market share of 80.57% in 2024 owing tthe greater accuracy offered by these studies, as compared tother clinical study designs
- European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Phase
1.2.3. Indication
1.2.4. Service Type
1.2.5. Sponsor
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Bottom-up Approach
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
1.12. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. EUROPE CLINICAL TRIALS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of new technology in clinical research
3.2.1.2. Shift toward personalized medicine
3.2.1.3. Growing disease variation and prevalence
3.2.1.4. Growth in CRO market
3.2.2. Market Restraint Analysis
3.2.2.1. Regulations in new drug development
3.2.2.2. Pricing pressure
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. Analysis of total number of clinical trial studies conducted, by countries
3.3.4. Cost breakdown analysis for CRO's
3.3.5. Percent of outsourced vs in-house clinical trial categories
3.3.6. Cost breakdown analysis for CRO's by Phase I, II, & III
3.3.7. COVID-19 Impact Analysis
CHAPTER 4. EUROPE CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Europe Clinical Trials Market, Phase Movement Analysis
4.3. Europe Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
4.4. Phase I
4.4.1. Phase I Market, 2018 to 2030 (USD Million)
4.5. Phase II
4.5.1. Phase II Market, 2018 to 2030 (USD Million)
4.6. Phase III
4.6.1. Phase III Market, 2018 to 2030 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market, 2018 to 2030 (USD Million)
CHAPTER 5. EUROPE CLINICAL TRIALS MARKET: STUDY DESIGN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Europe Clinical Trials Market, Study Design Movement Analysis
5.3. Europe Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
5.4. Interventional studies
5.4.1. Interventional Studies Market, 2018 to 2030 (USD Million)
5.5. Observational studies
5.5.1. Observational Studies Market, 2018 to 2030 (USD Million)
5.6. Expanded access studies
5.6.1. Expanded Access Studies Market, 2018 to 2030 (USD Million)
CHAPTER 6. EUROPE CLINICAL TRIALS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Europe Clinical Trials Market, Indication Movement Analysis
6.3. Europe Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Autoimmune/inflammation
6.4.1. Autoimmune/Inflammation Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome (IBS)
6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain Management
6.5.1. Pain Management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic Pain
6.5.2.1. Chronic Pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute Pain
6.5.3.1. Acute Pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood Cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid Tumors
6.6.3.1. Solid Tumors Market, 2018 to 2030 (USD Million)
6.6.4. Other
6.6.4.1. Other Market, 2018 to 2030 (USD Million)
6.7. CNS conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's Disease (PD)
6.7.3.1. Parkinson's Disease (PD) Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's Disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Traumatic Brain Injury (TBI)
6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 to 2030 (USD Million)
6.7.7. Amyotrophic Lateral Sclerosis (ALS)
6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.8. Muscle Regeneration
6.7.8.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.9. Others
6.7.9.1. Other Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Cardiovascular
6.10.1. Cardiovascular Market, 2018 to 2030 (USD Million)
6.11. Others
6.11.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 7. EUROPE CLINICAL TRIALS MARKET: SERVICE TYPE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Europe Clinical Trials Market, Service Type Movement Analysis
7.3. Europe Clinical Trials Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
7.4. Protocol Designing
7.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
7.5. Site Identification
7.5.1. Site Identification Market, 2018 to 2030 (USD Million)
7.6. Patient Recruitment
7.6.1. Patient Recruitment Market, 2018 to 2030 (USD Million)
7.7. Laboratory Services
7.7.1. Laboratory Services Market, 2018 to 2030 (USD Million)
7.8. Bioanalytical Testing Services
7.8.1. Bioanalytical Testing Services Market, 2018 to 2030 (USD Million)
7.9. Clinical Trial Data Management Services
7.9.1. Clinical Trial Data Management Services Market, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 8. EUROPE CLINICAL TRIALS MARKET: SPONSOR ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Europe Clinical Trials Market, Sponsor Movement Analysis
8.3. Europe Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & biopharmaceutical companies
8.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.5. Medical device companies
8.5.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 9. EUROPE CLINICAL TRIALS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Europe
9.3.1. Europe Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. UK Market Estimates and Forecasts, 2018-2030
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Germany Market Estimates and Forecasts, 2018-2030
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. France Market Estimates and Forecasts, 2018-2030
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Italy Market Estimates and Forecasts, 2018-2030
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Spain Market Estimates and Forecasts, 2018-2030
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Sweden Market Estimates and Forecasts, 2018-2030
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Denmark Market Estimates and Forecasts, 2018-2030
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Norway Market Estimates and Forecasts, 2018-2030
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Company Categorization
10.2. Company Market Position Analysis, 2023
10.3. Company Profiles
10.3.1. IQVIA Holdings, Inc.,
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Parexel International Corporation
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PPD, Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Syneos Health
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Eli Lilly and Company
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Novo Nordisk A/S
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Dr. Notghi Contract Research GmbH
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Charite Research Organisation GmbH
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Janssen Global Services, LLC
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. KFGN
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Clariness
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Invisio Clinical Studies Consulting GmbH
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Phase
1.2.3. Indication
1.2.4. Service Type
1.2.5. Sponsor
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Bottom-up Approach
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
1.12. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. EUROPE CLINICAL TRIALS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of new technology in clinical research
3.2.1.2. Shift toward personalized medicine
3.2.1.3. Growing disease variation and prevalence
3.2.1.4. Growth in CRO market
3.2.2. Market Restraint Analysis
3.2.2.1. Regulations in new drug development
3.2.2.2. Pricing pressure
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. Analysis of total number of clinical trial studies conducted, by countries
3.3.4. Cost breakdown analysis for CRO's
3.3.5. Percent of outsourced vs in-house clinical trial categories
3.3.6. Cost breakdown analysis for CRO's by Phase I, II, & III
3.3.7. COVID-19 Impact Analysis
CHAPTER 4. EUROPE CLINICAL TRIALS MARKET: PHASE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Europe Clinical Trials Market, Phase Movement Analysis
4.3. Europe Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
4.4. Phase I
4.4.1. Phase I Market, 2018 to 2030 (USD Million)
4.5. Phase II
4.5.1. Phase II Market, 2018 to 2030 (USD Million)
4.6. Phase III
4.6.1. Phase III Market, 2018 to 2030 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market, 2018 to 2030 (USD Million)
CHAPTER 5. EUROPE CLINICAL TRIALS MARKET: STUDY DESIGN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Europe Clinical Trials Market, Study Design Movement Analysis
5.3. Europe Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
5.4. Interventional studies
5.4.1. Interventional Studies Market, 2018 to 2030 (USD Million)
5.5. Observational studies
5.5.1. Observational Studies Market, 2018 to 2030 (USD Million)
5.6. Expanded access studies
5.6.1. Expanded Access Studies Market, 2018 to 2030 (USD Million)
CHAPTER 6. EUROPE CLINICAL TRIALS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Europe Clinical Trials Market, Indication Movement Analysis
6.3. Europe Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Autoimmune/inflammation
6.4.1. Autoimmune/Inflammation Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome (IBS)
6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain Management
6.5.1. Pain Management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic Pain
6.5.2.1. Chronic Pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute Pain
6.5.3.1. Acute Pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood Cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid Tumors
6.6.3.1. Solid Tumors Market, 2018 to 2030 (USD Million)
6.6.4. Other
6.6.4.1. Other Market, 2018 to 2030 (USD Million)
6.7. CNS conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's Disease (PD)
6.7.3.1. Parkinson's Disease (PD) Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's Disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Traumatic Brain Injury (TBI)
6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 to 2030 (USD Million)
6.7.7. Amyotrophic Lateral Sclerosis (ALS)
6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.8. Muscle Regeneration
6.7.8.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.9. Others
6.7.9.1. Other Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Cardiovascular
6.10.1. Cardiovascular Market, 2018 to 2030 (USD Million)
6.11. Others
6.11.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 7. EUROPE CLINICAL TRIALS MARKET: SERVICE TYPE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Europe Clinical Trials Market, Service Type Movement Analysis
7.3. Europe Clinical Trials Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
7.4. Protocol Designing
7.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
7.5. Site Identification
7.5.1. Site Identification Market, 2018 to 2030 (USD Million)
7.6. Patient Recruitment
7.6.1. Patient Recruitment Market, 2018 to 2030 (USD Million)
7.7. Laboratory Services
7.7.1. Laboratory Services Market, 2018 to 2030 (USD Million)
7.8. Bioanalytical Testing Services
7.8.1. Bioanalytical Testing Services Market, 2018 to 2030 (USD Million)
7.9. Clinical Trial Data Management Services
7.9.1. Clinical Trial Data Management Services Market, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 8. EUROPE CLINICAL TRIALS MARKET: SPONSOR ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Europe Clinical Trials Market, Sponsor Movement Analysis
8.3. Europe Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & biopharmaceutical companies
8.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.5. Medical device companies
8.5.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 to 2030 (USD Million)
CHAPTER 9. EUROPE CLINICAL TRIALS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Europe
9.3.1. Europe Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. UK Market Estimates and Forecasts, 2018-2030
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Germany Market Estimates and Forecasts, 2018-2030
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. France Market Estimates and Forecasts, 2018-2030
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Italy Market Estimates and Forecasts, 2018-2030
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Spain Market Estimates and Forecasts, 2018-2030
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Sweden Market Estimates and Forecasts, 2018-2030
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Denmark Market Estimates and Forecasts, 2018-2030
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Norway Market Estimates and Forecasts, 2018-2030
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Company Categorization
10.2. Company Market Position Analysis, 2023
10.3. Company Profiles
10.3.1. IQVIA Holdings, Inc.,
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Parexel International Corporation
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PPD, Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Syneos Health
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Eli Lilly and Company
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Novo Nordisk A/S
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Dr. Notghi Contract Research GmbH
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Charite Research Organisation GmbH
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Janssen Global Services, LLC
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. KFGN
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Clariness
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Invisio Clinical Studies Consulting GmbH
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
